Polatuzumab Vedotin Plus R-CHP for Newly Diagnosed Diffuse Large B-Cell Lymphoma: John Burke, MD

For patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL), less than half of patients are cured with the current standard of care, and effective treatments are greatly needed. In the phase 3 POLARIX trial, a team of researchers investigated the efficacy of polatuzumab vedotin in combination with R-CHP (rituximab/cyclophosphamide/doxorubicin/prednisone) for this population. In this interview, one of the study's investigators, Dr. John Burke of Rocky Mountain Cancer Centers and the U...

Continue reading

Lisocabtagene Maraleucel Approved for Relapsed/Refractory Large B-Cell Lymphomas

The FDA has approved lisocabtagene maraleucel (Breyanzi®, Juno Therapeutics) for patients with relapsed/refractory large B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DCBLC transformed from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal B-cell lymphoma, and grade 3B follicular lymphoma, who have progressive disease following at least two prior lines of systemic therapy. Lisocabtagene maraleucel is not indicated for patie...

Continue reading

DLBCL: Complete Surgical Resection Before Immunochemotherapy May Benefit Younger Patients

Complete surgical resection prior to immunochemotherapy may benefit patients with diffuse large B-cell lymphoma (DLBCL) under the age of 60, according to results from a subgroup analysis of the phase 3 PETAL trial. Unlike the treatment of solid tumors, the treatment of lymphoma focuses almost exclusively on systemic therapy. Surgical resection is generally only performed for diagnostic value, and little evidence exists regarding its impact on outcomes for patients with lymphoma. "Modern imaging ...

Continue reading

Selinexor Approved for R/R Diffuse Large B-Cell Lymphoma

Accelerated approval was granted to selinexor (Xpovio®, Karyopharm Therapeutics) to treat adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), including those with DLBCL resulting from follicular lymphoma, after receiving at least two prior lines of systemic therapy. Selinexor had previously been approved in combination with dexamethasone for adult patients with R/R multiple myeloma who were previously treated with at least four therapies and whose disease is refr...

Continue reading

Ibrutinib Plus R-CHOP for Non-Germinal Center DLBCL With Wyndham Wilson, MD

Diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin lymphoma, has a 5-year survival rate of 63%. However, patients with non-germinal center B-cell-like (non-GCB) disease and high MYC and BCL2 expression face a poorer prognosis, with limited treatment options. In the phase 3 PHOENIX trial, Wyndham Wilson, MD, the Head of the Lymphoma Therapeutics Section at the National Cancer Institute, and colleagues investigated a combination of ibrutinib and rituximab, cyclophosphami...

Continue reading

Polatuzumab Vedotin Approved in Relapsed/Refractory DLBCL

The FDA has now granted accelerated approval to polatuzumab vedotin (Polivy®, Genentech, Inc.) in combination with bendamustine and a rituximab product for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, following two or more prior lines of therapy. Estimates of five-year survival for DLBCL have been reported at 62.0% in the United States and 55.4% in Europe. Over 50% of patients with advanced-stage, previously untreated DLBCL experience complet...

Continue reading

Rituximab/Lenalidomide/Ibrutinib Effective in DLBCL

A phase 2 study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting revealed that a combination of rituximab (Rituxan®, Genentech USA, Inc), lenalidomide (Revlimid®, Celgene Corporation), and ibrutinib (Imbruvica®, Janssen Biotech, Inc) demonstrates overall response in adult patients with previously untreated non-germinal center B-cell (non-GCB)–like subtype diffuse large B-cell lymphoma (DLBCL). Rituximab, which targets abnormal B cells and reduces their lifespan, is al...

Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2022 Oncology Data Advisor. All rights reserved.